Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Botswana reviews proposed 33% power tariff hike today
    • PM Modi meets Prince and Princess of Wales for climate talks
    • Petrol price jump lifts South Africa inflation as SARB weighs rates
    • Ebola adds 60 cases in a day as Congo deaths hit 5,568
    • Dubai Airports expects over 70 million guests in 2026
    • ASEAN signs digital economy pact eyeing $2 trillion by 2030
    • Over 9 million visitors lift Tunisia tourism income 3.4%
    • Damascus becomes Air Arabia Dammam’s second foreign route
    News KepriNews Kepri
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    News KepriNews Kepri
    Home » Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
    PR Newswire

    Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

    October 2, 2024
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email

    –  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV

    HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ — Hetero, India’s leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis (PrEP).

    Hetero Logo

    This collaboration marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions. Lenacapavir is a breakthrough HIV-1 capsid inhibitor that works with other antiretroviral drugs to treat multi-drug-resistant HIV-1 infections. It has a unique ability to target multiple stages of the HIV lifecycle, making it highly effective for patients with limited treatment options.

    Expanding Access to Affordable HIV Treatment

    Dr. Vamsi Krishna Bandi, Managing Director of Hetero Group of Companies, emphasized: “This partnership with Gilead Sciences strengthens our resolve to push the boundaries of HIV prevention and treatment. For over three decades, Hetero has been at the forefront of the global fight against HIV/AIDS, pioneering affordable, life-saving treatments where the need is greatest. With over 30 combinations addressing nearly 40%* of the global HIV/AIDS population, we take immense pride in the positive impact our efforts have made so far. We will further bring quick access to lenacapavir in Africa, India and other LMICs, where we’ve been a cornerstone of HIV/AIDS care.”

    By leveraging our strong research focus, unparalleled manufacturing scale and distribution expertise, we are primed to rapidly expand access to lenacapavir in all 120 high-incidence, resource-limited countries. With our generic lenacapavir, we will reach communities beyond the usual access points, ensuring that even in the most underserved and remote areas, people receive the effective and affordable HIV prevention and treatment they deserve, he added.

    Groundbreaking Clinical Results

    Earlier this month, Gilead announced promising results from a pivotal Phase 3 clinical trial. The interim analysis demonstrated that lenacapavir reduced HIV infections by 96% compared to the background HIV incidence. This highlights the transformative potential of lenacapavir as a long-acting treatment and prevention option.1

    Lenacapavir is also being studied as a long-acting HIV prevention drug in ongoing clinical trials. This drug’s long-acting version can be administered every six months via a subcutaneous injection, following an initial oral loading dose. Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and received U.S. FDA approval in December 2022. The use of lenacapavir for the prevention of HIV is investigational and is not approved anywhere globally.

    About Hetero

    Hetero is a globally renowned vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 30+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world. For more information on Hetero, please visit www.hetero.com.

    Logo – https://mma.prnewswire.com/media/2521820/4947441/Hetero_Logo.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/hetero-signs-voluntary-licensing-agreement-with-gilead-to-transform-global-hiv-response-expanding-access-to-groundbreaking-lenacapavir-to-120-high-incidence-countries-302265679.html


    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    Subway® unveils Blueprint, a reimagined restaurant and brand experience for EMEA

    October 8, 2026

    DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity

    September 30, 2026

    GoChengdu: The Sun and Immortal Bird Flies Over the Nile: “Dialogue Between Solar Civilizations–Chengdu Panda Week Series” Held in Cairo

    September 21, 2026
    Latest News
    Business

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    The state energy regulator has officially initiated a comprehensive public review process regarding a substantial electricity rate increase requested by the national utility provider. Confirming the scope of this critical regulatory review, Botswana opens consultations on proposed 33 percent power

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    ASEAN signs digital economy pact eyeing $2 trillion by 2030

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 News Kepri | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.